Camstent Coatings
Our Technology
Camstent novel Bacteriaphobic® Coating Technology
The Problem
A urinary tract infection (UTI) is a bacterial infection of the bladder, urethra, or kidneys. Bacteria can form biofilms on surfaces like catheters, protecting them from the immune system and antibiotics. In 2022, about 236 million outpatient antibiotic prescriptions were written in the U.S., with 10% for UTIs. In England, antibiotic use is 17 daily doses per 1,000 people, with UTIs still accounting for much community antibiotic prescribing. Cutting unnecessary antibiotic use is key to slowing resistance, reducing side effects, and preserving effective treatments.
Urinary Tract Infections (UTI’s) resulting from catheter use are the leading hospital-acquired infection in the U.S., costing $13,793 per case. In the UK, each case costs around £2,000, with Foley catheter use contributing to £1–2.5 billion in annual NHS costs and ~2,100 deaths.
Antimicrobial resistance (AMR) occurs when bacteria adapt to survive treatment, making infections harder to cure. It is estimated that bacterial Antimicrobial Resistant (AMR) was directly responsible for 1.27 million global deaths in 2019 and contributed to 4.95 million deaths. This will increase up to 10 million by 2050. In addition to death and disability, AMR has significant economic costs. The World Bank estimates that AMR could result in US$ 1 trillion additional healthcare costs by 2050, and US$ 1 trillion to US$ 3.4 trillion Gross Domestic Product (GDP) losses per year by 2030.
Please click here to view results from clinical trials demonstrating lack of efficacy for existing products on the market.
The Solution
Camstent has developed a micro-thin patented polymer coating that inhibits the formation of biofilms. The coating also reduces friction to aid insertion/withdrawal and for added patient comfort.
Camstent Bacteriaphobic® polymer coating can be applied to silicone and many other plastic surfaces. We have a clinical investigation in progress to demonstrate the following performances of catheter coating:
- Change in the number of days in which bacterial concentrations are greater than 105 CFU/mL in coated catheters, as compared to uncoated control catheters
- Change in the number of cases experiencing Symptomatic Bacteriuria (CAUTI) coated catheters vs. uncoated controls
- Change in the number of cases receiving prophylactic or therapeutic Antibiotics during catheter use in coated catheters vs. uncoated controls
Advantages Of Our Unique Coating
The Camstent Bacteriaphobic® coating technology offers unique clinical advantages:
